CPX-351 in FLT3-mutated acute myeloid leukemia

CPX-351, a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a 1:5 molar ratio, is approved for the treatment of newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes. In a pivotal phase III trial, CPX-351 significantly improved ove...

Descripción completa

Detalles Bibliográficos
Autores principales: Andrews, Claire, Pullarkat, Vinod, Recher, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691756/
https://www.ncbi.nlm.nih.gov/pubmed/38044999
http://dx.doi.org/10.3389/fonc.2023.1271722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691756/
https://www.ncbi.nlm.nih.gov/pubmed/38044999
http://dx.doi.org/10.3389/fonc.2023.1271722

Ejemplares similares